{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T05:10:51Z","timestamp":1759641051870,"version":"build-2065373602"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,4]]},"DOI":"10.7759\/cureus.93846","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:42:11Z","timestamp":1759639331000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Despina","family":"Nicolaou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Nicolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savvas","family":"Christou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2023.11.005","article-title":"A systematic review on idiopathic intracranial hypertension comorbid with polycystic ovarian syndrome and its consequences","volume":"292","author":"Rzewuska N","year":"2024","unstructured":"Rzewuska N, Kunicki J, Pieniak K, Laskus P, Zabielska B, Smolarczyk R, Kunicki M. A systematic review on idiopathic intracranial hypertension comorbid with polycystic ovarian syndrome and its consequences. Eur J Obstet Gynecol Reprod Biol. 2024, 292:1-7. 10.1016\/j.ejogrb.2023.11.005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/life11060472","article-title":"Current perspectives on idiopathic intracranial hypertension without papilloedema","volume":"11","author":"Mollan SP","year":"2021","unstructured":"Mollan SP, Chong YJ, Grech O, Sinclair AJ, Wakerley BR. Current perspectives on idiopathic intracranial hypertension without papilloedema. Life (Basel). 2021, 11:10.3390\/life11060472","journal-title":"Life (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07563-z","article-title":"Idiopathic intracranial hypertension without papilledema maybe underdiagnosed","volume":"45","author":"Emekli AS","year":"2024","unstructured":"Emekli AS, Hines DA, Miller NJ, Schulte A, Kaufman D. Idiopathic intracranial hypertension without papilledema maybe underdiagnosed. Neurol Sci. 2024, 45:5077-81. 10.1007\/s10072-024-07563-z","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad003","article-title":"The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial","volume":"146","author":"Mitchell JL","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK, et al.. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023, 146:1821-30. 10.1093\/brain\/awad003","journal-title":"Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01631-z","article-title":"Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension","volume":"24","author":"Krajnc N","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S, et al.. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023, 24:89. 10.1186\/s10194-023-01631-z","journal-title":"J Headache Pain"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/151695","article-title":"GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons","volume":"31","author":"Papaetis GS","year":"2022","unstructured":"Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons. Adv Clin Exp Med. 2022, 31:1265-74. 10.17219\/acem\/151695","journal-title":"Adv Clin Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0972","article-title":"A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus","volume":"9","author":"Botfield HF","year":"2017","unstructured":"Botfield HF, Uldall MS, Westgate CS, et al.. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017, 9:10.1126\/scitranslmed.aan0972","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-025-00652-x","article-title":"Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats","volume":"22","author":"Jensen MN","year":"2025","unstructured":"Jensen MN, Israelsen IM, Wardman JH, et al.. Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats. Fluids Barriers CNS. 2025, 22:41. 10.1186\/s12987-025-00652-x","journal-title":"Fluids Barriers CNS"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02908-y","article-title":"Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension","volume":"38","author":"Grech O","year":"2024","unstructured":"Grech O, Mitchell JL, Lyons HS, et al.. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension. Eye (Lond). 2024, 38:1374-9. 10.1038\/s41433-023-02908-y","journal-title":"Eye (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52300","article-title":"Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study","volume":"12","author":"Azzam AY","year":"2025","unstructured":"Azzam AY, Essibayi MA, Vaishnav D, et al.. Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study. Ann Clin Transl Neurol. 2025, 12:746-55. 10.1002\/acn3.52300","journal-title":"Ann Clin Transl Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01497-x","article-title":"Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis","volume":"23","author":"Hu Y","year":"2023","unstructured":"Hu Y, Song X, Hamiti S, et al.. Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. BMC Endocr Disord. 2023, 23:250. 10.1186\/s12902-023-01497-x","journal-title":"BMC Endocr Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou L","year":"2023","unstructured":"Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023, 23:245. 10.1186\/s12902-023-01500-5","journal-title":"BMC Endocr Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01730-8","article-title":"Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials","volume":"17","author":"Sridharan K","year":"2025","unstructured":"Sridharan K, Sivaramakrishnan G. Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials. Diabetol Metab Syndr. 2025, 17:168. 10.1186\/s13098-025-01730-8","journal-title":"Diabetol Metab Syndr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00189","article-title":"The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome","volume":"10","author":"Dawson AJ","year":"2019","unstructured":"Dawson AJ, Sathyapalan T, Vince R, Coady AM, Ajjan RA, Kilpatrick ES, Atkin SL. The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2019, 10:189. 10.3389\/fendo.2019.00189","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jog.16296","article-title":"Effects of exenatide plus metformin versus metformin alone on insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"51","author":"Al-Qudah AA","year":"2025","unstructured":"Al-Qudah AA, Al-Hanaktah M, Albadaineh R. Effects of exenatide plus metformin versus metformin alone on insulin resistance in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2025, 51:e16296. 10.1111\/jog.16296","journal-title":"J Obstet Gynaecol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417061-the-role-of-exenatide-a-glucagon-like-peptide-1-glp-1-receptor-agonist-in-idiopathic-intracranial-hypertension-and-polycystic-ovary-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:42:15Z","timestamp":1759639335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417061-the-role-of-exenatide-a-glucagon-like-peptide-1-glp-1-receptor-agonist-in-idiopathic-intracranial-hypertension-and-polycystic-ovary-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.93846","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,4]]}}}